Mechanism of action

Efficacy Efficacy

Person depicted is not an actual HCP.

TURALIO acts as a CSF-1 regulator to target the tumor and interrupt cell signaling responsible for tumor growth and inflammation1,6

Pexidartinib is a small-molecule tyrosine kinase inhibitor that targets colony-stimulating factor 1 receptor (CSF-1R), KIT proto-oncogene receptor
tyrosine kinase (KIT), and FMS-like tyrosine kinase 3 (FLT3) harboring an internal tandem duplication (ITD) mutation

Overexpression of the CSF-1R ligand promotes cell proliferation and accumulation in the synovium

TURALIO is the only FDA-approved targeted therapy for TGCT1

Learn about the dosage regimen for TURALIO

Interested in TURALIO?

Get more information and resources


References: 1. TURALIO [package insert]. Basking Ridge, NJ: Daiichi Sankyo, Inc; 2023. 2. Eisenhauer EA et al. Eur J Cancer. 2009;45(2): 228-247. 3. Data on file. Daiichi Sankyo. 4. Healey JH et al. Slides presented at: Musculoskeletal Tumor Society Annual Meeting; October 2-4, 2019; Portland, Oregon. Presentation 46. 5. Tap WD et al; ENLIVEN investigators. Lancet. 2019;394(10197): 478-487. 6. West RB et al. Proc Natl Acad Sci U S A. 2006;103(3): 690-695. 7. Tap WD et al. N Engl J Med. 2015;373(5)(suppl):1-39. 8. Oncologic Drugs Advisory Committee. NDA 211810. Pexidartinib. U.S. Food & Drug Administration; May 14, 2019. Accessed October 19, 2021. 9. Gelderblom H et al. Cancer. 2021;127(6):884-893.